GenoMed's Dr. David Moskowitz Featured on Wall Street Reporter
SARASOTA, Fla., Dec 11, 2001 (BUSINESS WIRE) -- GenoMed Inc.-- ("the Company"
or "GenoMed") (Pink Sheets:GMED), a St. Louis, Missouri based medical genomics
biotechnology company, announced today that its Founder and Chief Medical
Officer, Dr. David Moskowitz is featured on Wall Street Reporter
(http://www.wallstreetreporter.com) discussing GenoMed's foray into disease gene
discovery.
In describing the company's focus, Dr. Moskowitz states, "We are looking in the
part of the genome that, up until now, has been overlooked. We are fishing for
disease genes using our DiseaseGeneNet with the intent of compiling this
information on our proprietary HealthChip. This will essentially allow us to
tell a person's genetic fortune. Once we can tell someone's predisposition to a
disease, we can give them medication specifically targeted against their disease
process. It is clear, by targeting a gene or group of genes early in the disease
process, we can play a major role in delaying the course of disease or even
preventing it altogether."
In reference to the profit potential of disease gene discovery, Dr. Moskowitz
goes on to say, "The Return on Investment in this particular area is
astronomical. We plan to increase shareholder value by continuing to build our
intellectual property portfolio. We believe that what is taking place in medical
genomics is essentially a land grab and we intend to patent as many disease
associated genes as possible in the next 24 months. It is estimated by Daniel
Cohen of Genset that a single disease gene is worth from 40 to 80 million
dollars, and we expect to find hundreds of these. Because we have one foot
firmly in the clinic and the other foot in state of the art genomics, we expect
to be the leader in this new translational period which amounts to a
revolutionary period in medicine."
About GenoMed
GenoMed was founded with the sole purpose of translating knowledge of disease
genes into better patient outcomes as rapidly and as safely as possible. The
Company's business model specifically links improved patient outcomes to Company
revenues through clinical treatment and genetic diagnoses of diseases.
For additional information please visit genomedics.com and/or contact
Craig Hall @ (941) 366-6677 or email at chall@floridafunds.com.
CONTACT: GenoMed, Inc., Sarasota
Craig Hall, 941/366-6677
chall@floridafunds.com
genomedics.com |
